Abbott Laboratories (ABT) vs Sanofi (SNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sanofi (SNY) has outperformed Abbott Laboratories (ABT) over the past year, losing 18.3% versus a loss of 26.6%. Over five years, ABT leads with a -16.0% price change compared with -17.7% for SNY. Abbott Laboratories is the larger company by market cap ($170.43 billion vs $96.40 billion), about 1.8 times the size.
On valuation, Sanofi trades at a lower forward P/E (7.4x vs 16.2x for Abbott Laboratories). Sanofi offers the higher dividend yield (10.24% vs 2.52%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABT | SNY |
|---|---|---|
| Share price | $98.49 | $40.23 |
| Market cap | $170.43B | $96.40B |
| 1-day change | -0.24% | +0.07% |
| YTD return | -21.39% | -17.04% |
| 1-year return | -26.65% | -18.29% |
| 5-year return | -15.97% | -17.71% |
| P/E ratio (TTM) | 31.77 | 21.17 |
| Forward P/E | 16.24 | 7.45 |
| EPS (TTM) | $3.10 | $1.90 |
| Dividend yield | 2.52% | 10.24% |
| Annual dividend | $2.48 | $4.12 |
| Revenue (latest FY) | $44.33B | — |
| Revenue growth (YoY) | +5.67% | — |
| Net income (latest FY) | $6.52B | — |
| Gross margin | 56.42% | — |
| Operating margin | 18.17% | — |
| Net margin | 14.72% | — |
| 52-week high | $135.13 | $52.68 |
| 52-week low | $81.97 | $39.18 |
| Distance from 52-week high | -27.11% | -23.63% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +22.57% | +33.26% |
| Average volume | 9.56M | 2.89M |
| Shares outstanding | 1.73B | 2.40B |
| Employees | 122,000 | 74,846 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Abbott Laboratories trades at a higher earnings multiple (31.8x vs 21.2x trailing P/E).
- Sanofi offers a meaningfully higher dividend yield (10.24% vs 2.52%).
About Abbott Laboratories
ABT stock →Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Health Care · Biotechnology: Pharmaceutical Preparations · 122,000 employees
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
ABT vs SNY FAQ
Which is bigger, Abbott Laboratories or Sanofi?
Abbott Laboratories (ABT) is larger, with a market capitalization of $170.43B compared with $96.40B for Sanofi (SNY).
Which stock has performed better over the past year, ABT or SNY?
SNY returned -18.29% over the past 12 months, compared with -26.65% for ABT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABT or SNY?
SNY has the lower trailing P/E at 21.2, versus 31.8 for ABT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Abbott Laboratories or Sanofi?
Sanofi has the higher yield at 10.24%, compared with 2.52% for Abbott Laboratories.
Are Abbott Laboratories and Sanofi in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.